Biohaven Pharma (BHVN) Announces Strategic Collaboration with Pfizer (PFE) for Commercialization of Rimegepant Outside the US
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Biohaven (BHVN) Defended at William Blair
November 9, 2021 11:58 AM ESTWilliam Blair analyst Tim Lugo is out defending Biohaven Pharmaceutical Holding (NYSE: BHVN) on weakness after the company agreed to a strategic deal with Pfizer (NYSE: PFE) versus an outright takeover.
The analyst commented, "We view Nurtec ODT as the... More
Biohaven Pharma (BHVN) and Pfizer (PFE) announce strategic collaboration for the global commercialization of NURTEC ODT outside the United States
November 9, 2021 7:47 AM ESTBiohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), a biopharmaceutical company with a portfolio of innovative, late-stage product candidates targeting neurological diseases including rare disorders, today reported financial results for the third quarter ended September 30, 2021, and provided a review of recent accomplishments and anticipated upcoming milestones.
NURTEC® ODT (rimegepant) continues to exceed expectations, reporting $136 million in net product revenue for the third quarter of 2021, totaling approximately $336 million in revenues and over 1,100,000 prescriptions from product launch to date - NURTEC ODT continues to be market leader for new oral migraine therapies and currently accounts for... MoreBiohaven Pharma (BHVN) Tops Q3 EPS by 49c; Reports Cash and Cash Equivalents of $523.9M
November 9, 2021 7:47 AM ESTBiohaven Pharma (NYSE: BHVN) reported Q3 EPS of ($1.91), $0.49 better than the analyst estimate of ($2.40). Revenue for the quarter came in at $135.7 million versus the consensus estimate of $128.4 million.
For earnings history and earnings-related data on Biohaven Pharma (BHVN) click here.
... MoreBiohaven Pharma (BHVN) Halted, News Pending
November 9, 2021 7:24 AM ESTBiohaven Pharma (NYSE: BHVN) Halted, News Pending
